Business Context and Reporting Period
This Form 8-K Current Report was filed by Nanoviricides, Inc. on March 9, 2010, reporting events that occurred on March 3, 2010. The filing details the entry into material definitive employment agreements with key executive officers and the unregistered sale of equity securities associated with these agreements.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compensation structures and equity issuances.
- Executive Compensation (Base Salary):
- Dr. Eugene Seymour (CEO/CFO) and Dr. Anil Diwan (Chairman/President): Minimum $250,000 annually.
- Dr. Jayant Tatake (VP R&D): $150,000 annually.
- Dr. Randall Barton (CSO): $150,000 annually.
- Equity Issuances (Initial Grant):
- Dr. Seymour and Dr. Diwan: 250,000 shares of Series A Convertible Preferred Stock each.
- Dr. Tatake: 93,750,000 shares of Series A Convertible Preferred Stock and 125,000 shares of common stock.
- Dr. Barton: 125,000 shares of common stock.
- Life Insurance: $2,000,000 coverage for Dr. Diwan (Company beneficiary: $1,000,000).
Material Changes and Compensation Triggers
The employment agreements include specific performance-based salary increases contingent on future corporate milestones:
- Financing Milestone: Base salaries for Dr. Seymour and Dr. Diwan increase to $275,000 if the company consummates a financing with gross proceeds of at least $5,000,000.
- Listing Milestone: Base salaries for Dr. Seymour and Dr. Diwan increase to $300,000 if the company becomes listed on a national stock exchange.
- Recurring Equity Grants:
- Dr. Seymour and Dr. Diwan: Additional 250,000 shares of Series A Convertible Preferred Stock on each anniversary.
- Dr. Tatake: Additional 93,750,000 shares of Series A Convertible Preferred Stock and 125,000 shares of common stock on each anniversary.
- Dr. Barton: Additional 125,000 shares of common stock on each anniversary.
Outlook, Risks, and Unusual Items
Equity Restrictions and Liquidity: The Series A Convertible Preferred Stock has no current market and can only be converted into common stock upon a change of control. All securities issued were sold as restricted securities under Section 4(2) of the Securities Act and Rule 506 of Regulation D, meaning they cannot be resold in the U.S. without registration or an exemption.
Management Commentary: The filing indicates a strategic focus on securing long-term leadership (four-year terms) and aligning executive compensation with significant capital raising and listing events.
Risks: The substantial issuance of 93,750,000 shares of Series A Preferred Stock to a single executive (Dr. Tatake) relative to the other executives represents a significant dilution event, though the conversion rights are currently limited to a change of control.
Investor Verification Checklist
- Verify the total authorized share count and the impact of the 93,750,000 Series A shares issued to Dr. Tatake on potential future dilution.
- Confirm the current cash position of the company to assess its ability to fund the new annual salary obligations (approx. $800,000+ in base salaries).
- Review the terms of the Series A Convertible Preferred Stock to understand the specific "change of control" definition and conversion mechanics.
- Monitor progress toward the $5,000,000 financing target and national stock exchange listing to determine if salary triggers will be activated.